Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling.
The primary biological function of the endogenous cellular prion protein has remained unclear. We investigated its biological function in the generation of cellular immune responses using cellular prion protein gene-specific small interfering ribonucleic acid in vivo and in vitro. Our results were confirmed by blocking cellular prion protein with monovalent antibodies and by using cellular prion protein-deficient and -transgenic mice. In vivo prion protein gene-small interfering ribonucleic acid treatment effects were of limited duration, restricted to secondary lymphoid organs and resulted in a 70% reduction of cellular prion protein expression in leukocytes. Disruption of cellular prion protein signalling augmented antigen-specific activation and proliferation, and enhanced T cell receptor signalling, resulting in zeta-chain-associated protein-70 phosphorylation and nuclear factor of activated T cells/activator protein 1 transcriptional activity. In vivo prion protein gene-small interfering ribonucleic acid treatment promoted T cell differentiation towards pro-inflammatory phenotypes and increased survival of antigen-specific T cells. Cellular prion protein silencing with small interfering ribonucleic acid also resulted in the worsening of actively induced and adoptively transferred experimental autoimmune encephalomyelitis. Finally, treatment of myelin basic protein(1-11) T cell receptor transgenic mice with prion protein gene-small interfering ribonucleic acid resulted in spontaneous experimental autoimmune encephalomyelitis. Thus, central nervous system autoimmune disease was modulated at all stages of disease: the generation of the T cell effector response, the elicitation of T effector function and the perpetuation of cellular immune responses. Our findings indicate that cellular prion protein regulates T cell receptor-mediated T cell activation, differentiation and survival. Defects in autoimmunity are restricted to the immune system and not the central nervous system. Our data identify cellular prion protein as a regulator of cellular immunological homoeostasis and suggest cellular prion protein as a novel potential target for therapeutic immunomodulation.
Hu
Wei
W
Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, USA.
Nessler
Stefan
S
Hemmer
Bernhard
B
Eagar
Todd N
TN
Kane
Lawrence P
LP
Leliveld
S Rutger
SR
Müller-Schiffmann
Andreas
A
Gocke
Anne R
AR
Lovett-Racke
Amy
A
Ben
Li-Hong
LH
Hussain
Rehana Z
RZ
Breil
Andreas
A
Elliott
Jeffrey L
JL
Puttaparthi
Krishna
K
Cravens
Petra D
PD
Singh
Mahendra P
MP
Petsch
Benjamin
B
Stitz
Lothar
L
Racke
Michael K
MK
Korth
Carsten
C
Stüve
Olaf
O
D000818:Animals; D020278:Demyelinating Autoimmune Diseases, CNS / Q000235:genetics* / Q000276:immunology; D005260:Female; D020868:Gene Silencing / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011328:Prions / Q000235:genetics* / Q000276:immunology; D034741:RNA, Small Interfering / Q000235:genetics; D011948:Receptors, Antigen, T-Cell / Q000502:physiology*; D015398:Signal Transduction / Q000276:immunology*
D011328:Prions; D034741:RNA, Small Interfering; D011948:Receptors, Antigen, T-Cell